Fenamic acid
Based on 1 Customer Validation
Fenamic acid (N-Phenylanthranilic acid, NPAA) is an orally active chloride channel blocker. Fenamic acid is the basic constituent of non-steroidal anti-inflammatory agents (NSAIA), and derives into mefenamic, tofenacin, flufenac acid and melofenac acid. Fenamic acid also acts as antibacterial and analgesic agent-.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.25%
- CAS 番号: 91-40-7
- 分子式: C13H11NO2
- 分子量:213.24
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-W040265R
Fenamic acid (Standard)Chloride Channel Blocker -
HY-101012
NPPBORCC Blocker -
HY-12693
R(+)-MethylindazoneChloride Channel Inhibitor -
HY-105917
EmidurdarAnion Channel Inhibitor -
HY-B0679
LubiprostoneGastrointestinal Agent -
HY-100611
CaCCinh-A01TMEM16A Inhibitor -
HY-103368
EactTMEM16A Activator -
HY-P0173A
ChlorotoxinAntitumor Agent -
HY-146320
ANO1-IN-1ANO1 Inhibitor -
HY-W001171
3-Hydroxyanthranilic acidTryptophan Metabolite -
HY-B0908
MeticraneChloride Channel Inhibitor -
HY-N2412
IrisolidoneVRAC Blocker
生物活性
製品説明
IC50 & Target
Chloride Channel[1]
体外実験
Fenamic acid (N-Phenylanthranilic acid, NPAA) (2.5 mM; 3 h) inhibits Cl- transportation and blocks 36C1- uptake and efflux in endothelial cells[1][2].
Fenamic acid exhibits selectivity to AKR1B10 (the tumor-marker) over human AR, and inhibits AKR1B10 with IC50s of 0.76 μM (Flufenamic acid), 1.6 μM (Mefenamic acid), 9.89 μM (Meclofenamic acid), respectively[4].
Fenamic acid (4-16 μg/mL; 72 h) inhibits 50% of Neisseria gonorrhoeae with an MIC50 value from 4 to 16 μg/mL (tolfenamic acid, flufenamic acid, and meclofenamic acid) in a low frequency of resistance[5].
Fenamic acid (2-8 μg/mL; 8 h) reduces the expression of the porinflammatory cytokines (IL-8, IL-6 and IL-?) by infected endocervical cells without (>128 μg/mL; 24 h) inhibition towards commensal Lactobacillus spp. belonging healthy female genital microbiota[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
Fenamic acid (N-Phenylanthranilic acid, NPAA) (350-700 mg/kg/day; o.p.; 4 d, 8 d, and 15 d) causes renal papillary necrosis and increases urinary renal papillary antigen-1 (RPA-1) in rats[3].
Fenamic acid (20 g/0.2 mL; i.p.) shows inhibitory effect against the abdominal constriction induced by acetic acid in mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar Hannover rats (8-10 weeks old; weighting 220-270 g)[3]
-
Dosage:50, 350, or up to 700 mg/kg
-
Administration:Oral gavage; once daily; 7 days or 14 days
-
Result:Increased absolute paired kidney weights (13.8% at 350 mg/kg and 21.2% at 700/500 mg/kg) and relative to body weight (10.5% at 350 mg/kg/day and 20.3% at 700/500 mg/kg/day).
Caused minimal papillary necrosis of tip with necrosis, hemorrhage, and inflammation of collecting ducts.
-
Animal Model:Male NMRI mice (weighting 20-25 g); abdominal constriction model (writhing test), induced by acetic acid[6]
-
Dosage:100 g/mL, each mice injected with 20 mL
-
Administration:Intraperitoneal injection; once
-
Result:Showed anti-nociceptive activity and inhibited the abdominal constriction with the maximal inhibition of 96.3% (Mefenamic acid).
化学情報
-
CAS 番号 91-40-7
-
性状 Solid
-
分子量 213.24
-
分子式 C13H11NO2
-
Color White to off-white
-
SMILES
O=C(O)C1=CC=CC=C1NC2=CC=CC=C2
-
別名
N-Phenylanthranilic acid
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
DMSO : 125 mg/mL (586.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 4.17 mg/mL (19.56 mM); Clear solution
This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Betton GR, et, al. Biomarkers of collecting duct injury in Han-Wistar and Sprague-Dawley rats treated with N-phenylanthranilic Acid. Toxicol Pathol. 2012 Jun;40(4):682-94. [Content Brief]
[2]. Mandel KG, et al. Characterization of a cyclic AMP-activated Cl-transport pathway in the apical membrane of a human colonic epithelial cell line. J Biol Chem. 1986 Jan 15. 261(2):704-12. [Content Brief]
[3]. Ueda S, et al. Chloride efflux in cyclic AMP-induced configurational change of bovine pulmonary artery endothelial cells. Circ Res. 1990 Apr. 66(4):957-67. [Content Brief]
[4]. Endo S, et al. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull. 2010. 33(5):886-90. [Content Brief]
[5]. Seong YJ, et al. Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020 Jun 23. 64(7):e02206-19. [Content Brief]
[6]. Almasirad A, et al. Synthesis and analgesic activity of 2-phenoxybenzoic acid and N-phenylanthranilic acid hydrazides. Biol Pharm Bull. 2006 Jun. 29(6):1180-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.6896 mL | 23.4482 mL | 46.8964 mL | 117.2410 mL |
| 5 mM | 0.9379 mL | 4.6896 mL | 9.3793 mL | 23.4482 mL | |
| 10 mM | 0.4690 mL | 2.3448 mL | 4.6896 mL | 11.7241 mL | |
| 15 mM | 0.3126 mL | 1.5632 mL | 3.1264 mL | 7.8161 mL | |
| 20 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL | 5.8620 mL | |
| 25 mM | 0.1876 mL | 0.9379 mL | 1.8759 mL | 4.6896 mL | |
| 30 mM | 0.1563 mL | 0.7816 mL | 1.5632 mL | 3.9080 mL | |
| 40 mM | 0.1172 mL | 0.5862 mL | 1.1724 mL | 2.9310 mL | |
| 50 mM | 0.0938 mL | 0.4690 mL | 0.9379 mL | 2.3448 mL | |
| 60 mM | 0.0782 mL | 0.3908 mL | 0.7816 mL | 1.9540 mL | |
| 80 mM | 0.0586 mL | 0.2931 mL | 0.5862 mL | 1.4655 mL | |
| 100 mM | 0.0469 mL | 0.2345 mL | 0.4690 mL | 1.1724 mL |
Fenamic acid 関連分類
HY-W040265 関連分類
Powered by Bioz